KRAS vaccine for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized vaccine designed to target cancers with specific KRAS gene mutations. It may be an option for adults whose advanced solid tumor (like pancreatic or lung cancer) has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is advanced (spread or cannot be removed by surgery) and has a specific KRAS mutation (G12C, G12D, G12R, or G12V).
- Standard treatments have stopped working, are not available, or you have minimal disease left after treatment.
- You must be willing to use effective birth control during and for 1 year after the study, if you or your partner could become pregnant.
- You must have a specific genetic marker called HLA-A*11:01.
- You have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.